Medpace Holdings Inc (MEDP) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Medpace Holdings Inc   (NASDAQ: MEDP)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Select the Financial Report: Select the Period:


Description of Medpace Holdings Inc's Business Segments


Medpace Holdings Inc. is recognized as a prominent Contract Research Organization (CRO) that delivers a wide array of clinical research services tailored specifically for pharmaceutical and biotechnology companies on a global scale. The company stands out due to its therapeutic expertise, adaptable service delivery models, and rigorous scientific methodologies.

Segments

Medpace operates primarily through two distinct yet interrelated segments:

1. Clinical Development Services:
This segment encompasses comprehensive clinical development capabilities, allowing it to support clients at every stage of the drug development process. Key offerings within this segment include:

- Study Design: Customizing study protocols that adhere to regulatory standards and scientific principles.
- Protocol Development: Collaborating with clients to establish clear, compliant, and effective clinical protocols.
- Regulatory Affairs: Assisting clients in navigating the labyrinth of regulatory requirements, facilitating submissions to agencies like the FDA and EMA.
- Site Management: Overseeing the entire process of site selection, initiation, and day-to-day management to ensure smooth operation and compliance with Good Clinical Practice (GCP).
- Clinical Monitoring: Conducting regular assessments of data collection at clinical trial sites to maintain quality and compliance.
- Data Management: Including database design, data cleaning, and the implementation of quality control processes to ensure integrity and accuracy of clinical trial data.
- Statistical Analysis: Performing advanced statistical analyses to derive insights from trial data, ensuring that results are interpretable and actionable.
- Medical Writing: Preparing scientific documents, study reports, and regulatory filings to ensure clarity and compliance.
- Quality Assurance: Enforcing rigorous quality assurance practices across all processes to uphold high standards and regulatory compliance in clinical trials.

Medpace has extensive experience across diverse therapeutic areas, including oncology, neurology, cardiology, infectious diseases, and rare diseases, allowing for tailored approaches suited to the specific challenges and requirements of different fields.

2. Laboratory Services:
The laboratory services segment enhances Medpaces clinical capabilities by providing detailed biomarker testing and central laboratory services essential for clinical trials. Key components include:

- Biomarker Testing: Utilization of advanced techniques for genomic, proteomic, and immune assays to support the discovery of biomarkers integral for patient stratification and monitoring efficacy.
- Central Laboratory Services: In-house, state-of-the-art laboratory facilities equipped with cutting-edge technologies such as next-generation sequencing, flow cytometry, immunoassays, and multiplex assays to ensure quality and reliability in testing.
- Sample Management: Comprehensive handling of biological samples, including collection, processing, and storage, ensuring that samples are managed according to strict regulatory guidelines.

Products

Medpace does not engage in the development or manufacturing of proprietary products. Instead, it serves as a facilitator for pharmaceutical and biotechnology clients, aiding them in the development of their own products, including new drugs, medical devices, and diagnostic tools. The focus on collaboration ensures that services are aligned with client goals and regulatory requirements with the aim of achieving efficient and successful product development.

Services

Medpace’s clinical research services are diverse and tailored to meet the various needs of its clients. Here are some detailed offerings:

1. Study Design: Expertly crafting scientifically robust study designs that are not only innovative but also compliant with the necessary guidelines and regulatory standards.

2. Site Management: Ensuring effective site management involves meticulous selection and training of site personnel, monitoring site performance, and facilitating investigator meetings.

3. Data Management: The data management process includes creating databases tailored to trial needs, implementing data entry protocols, and executing ongoing data quality checks.

4. Statistical Analysis: Utilizing a team of experienced biostatisticians, Medpace performs a comprehensive set of statistical analyses, ensuring that the interpretation of data aligns with regulatory standards and scientific rigor.

5. Medical Writing: This service encompasses the full spectrum of regulatory documentation, including clinical study reports, investigator brochures, and publications, all crafted to meet the required statutory language and clarity.

6. Quality Assurance: This program includes routine inspections, audits, and ongoing training to uphold the highest levels of compliance and quality in every trial phase.

Conclusion

Medpace’s extensive and diversified service offerings, coupled with its unique therapeutic expertise, position it as a premier partner for pharmaceutical and biotechnology firms. With a comprehensive suite of clinical research services that address each phase of drug development, Medpace is committed to facilitating the successful market entry of new therapeutic solutions, enhancing patient care globally. The companys focus on quality, compliance, and collaboration ensures that it remains at the forefront of the clinical research landscape.


Composition of Medpace Holdings Inc Revenues by Segments

 
Reportable    199.9 % of total Revenue
Metabolic    64.56 % of total Revenue
Oncology    58.05 % of total Revenue
Other    27.09 % of total Revenue
Central Nervous System    23.05 % of total Revenue
Cardiology    16.43 % of total Revenue
Antiviral and Anti Infective    10.72 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Reportable 1,413.94 199.9 %
Metabolic 456.63 64.56 %
Oncology 410.61 58.05 %
Other 191.60 27.09 %
Central Nervous System 163.07 23.05 %
Cardiology 116.24 16.43 %
Antiviral and Anti Infective 75.79 10.72 %
Total 707.33 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Reportable - -
Metabolic 286.77 % -
Oncology 117.76 % -
Other 29.57 % -
Central Nervous System 166.76 % -
Cardiology 98.42 % -
Antiviral and Anti Infective - -
Total 17.24 % 0.1 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable 288.33 20.39 %
Total 121.36 17.16 %




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Reportable - -
Total 34.46 % -2.02 %




Annual Report on Medpace Holdings Inc Divisions, Sales by Country

 
Metabolic   Metabolic Segment contribution to total sales 16.15 % of total Revenue
Oncology   Oncology Segment contribution to total sales 29.55 % of total Revenue
Other   Other Segment contribution to total sales 29.44 % of total Revenue
Central Nervous System   Central Nervous System Segment contribution to total sales 9.46 % of total Revenue
Cardiology   Cardiology Segment contribution to total sales 5.33 % of total Revenue
AVAI   AVAI Segment contribution to total sales 10.07 % of total Revenue


Twelve months ended 2025
MEDP s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Metabolic 408.55 16.15 %
Oncology 747.59 29.55 %
Other 744.96 29.44 %
Central Nervous System 239.37 9.46 %
Cardiology 134.94 5.33 %
Total 2,530.23 100 %
AVAI 254.84 10.07 %


Twelve months ended 2025
MEDP s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 451.12 17.83 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Metabolic -5.29 % -
Oncology 14.79 % -
Other 62.82 % -
Central Nervous System 3.87 % -
Cardiology -13.76 % -
Total 19.97 % 11.56 %
AVAI 40.04 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.